Allarity Therapeutics ended Q3 2026 with $24.1M in cash and a $6.2M net loss, mainly due to a $3.2M one-time manufacturing charge for its cancer drug stenoparib. The company expects Q4 earnings between $0.01 and $0.04 per share, driven by a $1M settlement gain with Novartis. Clinical trials for stenoparib in ovarian and lung cancer continue, supported by new patents and expanded lab services. Allarity aims to build revenue from its CLIA-certified lab alongside drug development.
Allarity Therapeutics reported a net loss of $6.2M in Q3 2026, influenced by a $3.2M one-time manufacturing charge. For readers following the health sector, here is Pluang's market snapshot as of Nov 13, 2026 19:41 WIB: out of 150 priced US health stocks, 99 rose and 43 fell. Notable movers include CTXR at USD 0.51 with a 4.21% decline and 84% sell order activity, TNGX at USD 24.00 down 3.42%, and BAX at USD 26.59 up 3.30% with 100% sell order activity.
Michelin has announced the total number of its voting rights and shares as of October 31, 2026. The company has 691,516,292 shares and 960,075,649 voting rights, considering 20,287,710 treasury shares. This disclosure complies with French regulations...
Michelin has disclosed the total number of voting rights and shares composing its capital as of October 31, 2026. The company reported 691,516,292 shares, with theoretical voting rights totaling 980,363,359 and exercisable voting rights at 960,075,64...
KeyBanc lowered its price target for YETI Holdings to $49, suggesting a 27.94% upside from the current $38.30 stock price. This follows YETI's reduction of its full-year adjusted sales growth forecast to about 6% from the previous 7-8%, citing consum...
Bernstein SocGen Group has reduced its price target for Applied Materials to $600, even though the company reported higher sales and profits in Q4 2026 driven by strong demand for semiconductor services, especially AI chips. Applied Materials posted ...
Boralex Inc. announced a private placement of $600 million Canadian dollars in green bonds, split into two series maturing in 2031 and 2036 with interest rates of 4.503% and 5.173%, respectively. This marks Boralex's first issuance of green corporate...
